9th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 19-21 July 2007, Sydney
Reports from this workshop
- Can nevirapine be safely substituted for other agents in those with high CD4 cell counts and virologic suppression?
- The growth hormone releasing factor analogue tesamorelin (TH9507) reduces visceral fat, but what else does it do?
- Does diabetes have the same impact on cardiovascular risk in HIV-positive patients as it does in the general population?
Reports by Michael Dube, for NATAP.org
Overall there continues to be a progressive evolution of our understanding of the causes of lipodystrophy, dyslipidemia, cardiovascular disease, and other adverse effects of ART. While certainly there have been no major breakthroughs in management, the availability of agents with lesser effects on these parameters and a few therapeutic interventions have begun to be applied.
Webcasts from the workshop are available online: